Advertisement
CRL vs WAT
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRL is a StrongBuy and WAT is a Hold.
CRL in +14.95% Uptrend, growing for three consecutive days on October 21, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where CRL advanced for three days, in 200 of 287 cases, the price rose further within the following month. The odds of a continued upward trend are 70%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on CRL as a result. In 54 of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 64%.
The Moving Average Convergence Divergence (MACD) for CRL just turned positive on October 20, 2026. Looking at past instances where CRL's MACD turned positive, the stock continued to rise in 30 of 48 cases over the following month. The odds of a continued upward trend are 62%.
The Aroon Indicator entered an Uptrend today. In 146 of 228 cases where CRL Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 64%.
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 70%.
CRL broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 2 (best 1 - 100 worst), indicating outstanding price growth. CRL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 13 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.798) is normal, around the industry mean (66.046). P/E Ratio (-71.699) is within average values for comparable stocks, (2.422). Projected Growth (PEG Ratio) (0.122) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (3.340) is also within normal values, averaging (9.775).
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 92 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 93 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CRL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 89, placing this stock worse than average.
WAT in downward trend: price may decline as a result of having broken its higher Bollinger Band on October 21, 2026
WAT broke above its upper Bollinger Band on October 21, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 38 similar instances where the stock broke above the upper band. In 29 of the 38 cases the stock fell afterwards. This puts the odds of success at 76%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for WAT moved out of overbought territory on September 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 32 similar instances where the indicator moved out of overbought territory. In 23 of the 32 cases, the stock moved lower in the following days. This puts the odds of a move lower at 72%.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where WAT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 63%.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on WAT as a result. In 60 of 93 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 65%.
The Moving Average Convergence Divergence (MACD) for WAT just turned positive on October 21, 2026. Looking at past instances where WAT's MACD turned positive, the stock continued to rise in 28 of 45 cases over the following month. The odds of a continued upward trend are 62%.
Following a +5.34% 3-day Advance, the price is estimated to grow further. Considering data from situations where WAT advanced for three days, in 175 of 277 cases, the price rose further within the following month. The odds of a continued upward trend are 63%.
The Aroon Indicator entered an Uptrend today. In 123 of 207 cases where WAT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 59%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 2 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 8 (best 1 - 100 worst), indicating outstanding price growth. WAT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 73 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. WAT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 89, placing this stock better than average.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 89 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 90 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.958) is normal, around the industry mean (66.046). WAT has a moderately high P/E Ratio (114.942) as compared to the industry average of (2.422). Projected Growth (PEG Ratio) (1.649) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (6.752) is also within normal values, averaging (9.775).
CRL | WAT | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 16 | 78 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 13 Undervalued | 90 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 73 | |
SMR RATING 1..100 | 93 | 89 | |
PRICE GROWTH RATING 1..100 | 2 | 8 | |
P/E GROWTH RATING 1..100 | 92 | 2 | |
SEASONALITY SCORE 1..100 | 50 | 85 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
CRL's Valuation (13) in the Miscellaneous Commercial Services industry is significantly better than the same rating for WAT (90) in the Medical Specialties industry. This means that CRL’s stock grew significantly faster than WAT’s over the last 12 months.
WAT's Profit vs Risk Rating (73) in the Medical Specialties industry is in the same range as CRL (100) in the Miscellaneous Commercial Services industry. This means that WAT’s stock grew similarly to CRL’s over the last 12 months.
WAT's SMR Rating (89) in the Medical Specialties industry is in the same range as CRL (93) in the Miscellaneous Commercial Services industry. This means that WAT’s stock grew similarly to CRL’s over the last 12 months.
CRL's Price Growth Rating (2) in the Miscellaneous Commercial Services industry is in the same range as WAT (8) in the Medical Specialties industry. This means that CRL’s stock grew similarly to WAT’s over the last 12 months.
WAT's P/E Growth Rating (2) in the Medical Specialties industry is significantly better than the same rating for CRL (92) in the Miscellaneous Commercial Services industry. This means that WAT’s stock grew significantly faster than CRL’s over the last 12 months.
| CRL | WAT | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 67% | 1 day ago 72% |
| Stochastic ODDS (%) | 1 day ago 82% | 1 day ago 69% |
| Momentum ODDS (%) | 1 day ago 64% | 1 day ago 65% |
| MACD ODDS (%) | 1 day ago 63% | 1 day ago 62% |
| TrendWeek ODDS (%) | 1 day ago 68% | 1 day ago 65% |
| TrendMonth ODDS (%) | 1 day ago 68% | 1 day ago 64% |
| Advances ODDS (%) | 2 days ago 70% | 2 days ago 63% |
| Declines ODDS (%) | 4 days ago 70% | 4 days ago 63% |
| BollingerBands ODDS (%) | 1 day ago 80% | 1 day ago 76% |
| Aroon ODDS (%) | 1 day ago 64% | 1 day ago 59% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CRL’s FA Score shows that 2 FA rating(s) are green while WAT’s FA Score has 2 green FA rating(s).
- CRL’s FA Score: 2 green, 3 red.
- WAT’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CRL’s TA Score shows that 4 TA indicator(s) are bullish while WAT’s TA Score has 4 bullish TA indicator(s).
- CRL’s TA Score: 4 bullish, 4 bearish.
- WAT’s TA Score: 4 bullish, 4 bearish.
Price Growth
CRL (@Medical Specialties) experienced а +14.20% price change this week, while WAT (@Medical Specialties) price change was +2.58% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was -3.15%. For the same industry, the average monthly price growth was -6.50%, and the average quarterly price growth was +42.74%.
Reported Earning Dates
CRL is expected to report earnings on Nov 04, 2026.
WAT is expected to report earnings on Nov 03, 2026.
Industries' Descriptions
@Medical Specialties (-3.15% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
Advertisement
CRL and
Correlation & Price change
A.I.dvisor indicates that over the last year, CRL has been closely correlated with IQV. These tickers have moved in lockstep 71% of the time. This A.I.-generated data suggests there is a high statistical probability that if CRL jumps, then IQV could also see price increases.
| Ticker / NAME | Correlation To CRL | 1D Price Change % | ||
|---|---|---|---|---|
| CRL | 100% | -1.51% | ||
| IQV - CRL | 71% Closely correlated | +0.61% | ||
| RGEN - CRL | 56% Loosely correlated | -0.72% | ||
| AZTA - CRL | 56% Loosely correlated | -2.04% | ||
| MEDP - CRL | 56% Loosely correlated | -1.29% | ||
| BRKR - CRL | 53% Loosely correlated | -3.04% | ||
More | ||||